18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO

Molecular imaging receives increased attention for selecting patients who will benefit from targeted anticancer therapies. Neo-ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) enrolled 455 women with invasive human epidermal growth factor receptor 2 (HER2)-positive breast cancer and compared rates of pathologic complete response (pCR) to neoadjuvant lapatinib, trastuzumab, and their combination. Each anti-HER2 therapy was given alone for 6 wk, followed by 12 wk of the same therapy plus weekly paclitaxel. The early metabolic effects of the anti-HER2 therapies on the primary tumors and their predictive values for pCR were assessed in a subset of patients. Methods: eighty-six patients underwent (18)F-FDG PET/CT at baseline and weeks 2 and 6 of anti-HER2 treatment. An imaging core laboratory provided central validation, and 2 independent reviewers, masked to assigned treatment arm and clinical outcomes, performed consensus (18)F-FDG PET/CT readings. Maximum standardized uptake value (SUVmax) reductions from baseline were used to measure metabolic response. Results: seventy-seven of the 86 enrolled patients presented an evaluable baseline (18)F-FDG PET/CT scan; of these, 68 and 66 were evaluable at weeks 2 and 6, respectively. Metabolic responses in the primary tumors were evident after 2 wk of targeted therapy and correlated highly with metabolic responses at week 6 (R(2) = 0.81). pCRs were associated with greater SUVmax reductions at both time points. Mean SUVmax reductions for pCR and non-pCR, respectively, were 54.3% versus 32.8% at week 2 (P = 0.02) and 61.5% versus 34.1% at week 6 (P = 0.02). (18)F-FDG PET/CT metabolic response rates at weeks 2 and 6 were 71.6% and 60%, respectively using European Organization for Research and Treatment of Cancer criteria; pCR rates were twice as high for (18)F-FDG PET/CT responders than nonresponders (week 2: 42% vs. 21%, P = 0.12; week 6: 44% vs. 19%, P = 0.05). Conclusion: early metabolic assessment using (18)F-FDG PET/CT can identify patients with an increased likelihood of pCR after neoadjuvant trastuzumab, lapatinib, or their combination when given with chemotherapy

De l'onco-gériatrie générale à la prise en charge spécifique du cancer du côlon-rectum chez la personne âgée

CLERMONT FD-BCIU-Santé (631132104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Trastuzumab et cardiotoxicité

CLERMONT FD-BCIU-Santé (631132104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Cancer du sein et grossesse

CLERMONT FD-BCIU-Santé (631132104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Traitement de consolidation ou de maintenance dans le cancer épithélial de l'ovaire de stade avancé (expérience du Centre Jean Perrin)

Après une revue de la littérature des traitements de consolidation ou de maintenance évalués dans le cancer épithélial de l'ovaire de stade avancé, l'auteur rapporte les modalités mises en œuvre au Centre de Lutte contre le Cancer Jean Perrin de Clermont-Ferrand. Une 1ère étude rétrospective reprend les données de 77 patientes traités, en situation de consolidation, par chimiothérapie intensive avec support de cellules souches hématopoïétiques. avec un recul médian de 189 mois, les médianes de survie sans rechute et de survie globale sont respectivement de 31 et 55 mois après le diagnostic. Cette option thérapeutique est donc tout à fait réalisable avec de bons résultats mais chez des patientes très sélectionnées. La 2ème étude rétrospective s'intéresse à l'apport de 3 cures de chimiothérapie supplémentaires après un traitement d'induction par chirurgie et six cures d'une association paclitaxel et carboplatine. Elle regroupe 125 patientes présentant un cancer de l'ovaire de stade IIIC ou IV. La prolongation du traitement ne semble pas apporter de bénéfice avec une survie globale identique dans les 2 bras. Par ailleurs, la décroissance du marqueur sérique CA 125 semble un facteur prédictif indépendant de réponse au traitement. Enfin, les données prospectives de 16 patientes randomisées dans un essai de phase III comparant un traitement de maintenance par erlotinib à une simple surveillance ont été analysées. Les survies sans récidives sont équivalentes dans les 2 groupes.CLERMONT FD-BCIU-Santé (631132104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Optimisation du traitement médical du cancer de la prostate hormono-résistant

CLERMONT FD-BCIU-Santé (631132104) / SudocPARIS-BIUP (751062107) / SudocSudocFranceF

Optimisation du traitement médical du cancer de la prostate hormono-résistant

CLERMONT FD-BCIU-Santé (631132104) / SudocPARIS-BIUP (751062107) / SudocSudocFranceF

The CMS Magnet Commissioning and the Development of an Improved CMS Conductor Suitable for Future Proposals

The success of the CMS Magnet commissioning has clearly shown the reliability of the conceptual choices for the cold mass. The reinforced conductor and the multi layer winding open the path for the conception of Large Magnet for HEP of the next generation. The paper will report about the basic results of the test campaign and then, after some critical considerations about the choices made for the CMS coil construction, possible improvements for the conductor construction are outlined. The main goal being to preserve long term RRR, and thus stability, of the insert and simplify the welding process to join the reinforcement alloy to the insert

18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.

Molecular imaging receives increased attention for selecting patients who will benefit from targeted anticancer therapies. Neo-ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) enrolled 455 women with invasive human epidermal growth factor receptor 2 (HER2)-positive breast cancer and compared rates of pathologic complete response (pCR) to neoadjuvant lapatinib, trastuzumab, and their combination. Each anti-HER2 therapy was given alone for 6 wk, followed by 12 wk of the same therapy plus weekly paclitaxel. The early metabolic effects of the anti-HER2 therapies on the primary tumors and their predictive values for pCR were assessed in a subset of patients.SCOPUS: ar.jinfo:eu-repo/semantics/publishe